Literature DB >> 11122539

Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions.

J C O'Shea1, J E Tcheng.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11122539     DOI： 10.1023/a:1026530804807

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  18 in total

1.  Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide.

Authors:  I F Charo; L Nannizzi; D R Phillips; M A Hsu; R M Scarborough
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

2.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

Authors:  D F Kong; R M Califf; D P Miller; D J Moliterno; H D White; R A Harrington; J E Tcheng; A M Lincoff; V Hasselblad; E J Topol
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

3.  Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

Authors:  M A Mascelli; E T Lance; L Damaraju; C L Wagner; H F Weisman; R E Jordan
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

4.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

Authors: 
Journal:  N Engl J Med       Date:  1997-06-12       Impact factor: 91.245

Review 5.  Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy.

Authors:  B S Coller
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

6.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

7.  Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

Authors:  H K Gold; L W Gimple; T Yasuda; R C Leinbach; W Werner; R Holt; R Jordan; H Berger; D Collen; B S Coller
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

8.  Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

Authors:  R A Harrington; N S Kleiman; K Kottke-Marchant; A M Lincoff; J E Tcheng; K N Sigmon; D Joseph; G Rios; K Trainor; D Rose
Journal:  Am J Cardiol       Date:  1995-12-15       Impact factor: 2.778

9.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.